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Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function
measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and
glaucomatous eyes receiving latanoprost 0.005% versus placebo.
Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One ran-
domly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects under-
went ﬁve diurnal measurements between 8:00 am and 4:00 pm consisting of Goldmann IOP, and PERGLA
measurements. A baseline examination was performed following a 4-week washout period, and repeat
examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed
over to receive the alternative therapy for 4 weeks following a second washout period, and underwent
repeat examination. Linear mixed-effect models were used for the analysis.
Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 ± 10.6 years)
were enrolled. The mean IOP (mm Hg) after latanoprost 0.005% therapy (14.9 ± 3.8) was signiﬁcantly
lower than baseline (18.8 ± 4.7, p < 0.001) or placebo (18.0 ± 4.3), with a mean reduction of 20 ± 13%.
Mean PERGLA amplitude (lV) and phase (p-radian) using latanoprost (0.49 ± 0.22 and 1.71 ± 0.22,
respectively) were similar (p > 0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and placebo (0.50 ± 0.24
and 1.72 ± 0.23). No signiﬁcant (p > 0.05) diurnal variation in PERGLA amplitude was observed at base-
line, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not signiﬁ-
cantly (p > 0.05) associated with PERGLA amplitude or phase.
Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with
improvement in RGC function measured with PERGLA.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Glaucoma is a progressive optic neuropathy known to cause
progressive loss of retinal ganglion cells (RGC) and their axons
(Johnson & Morrison, 2009; Varma, Peeples, Walt, & Bramley,
2008; Weinreb & Khaw, 2004). The pattern electroretinogram opti-
mized for glaucoma (PERGLA) is a non-invasive technology that
objectively measures RGC function (Bowd, Tafreshi, et al., 2009;
Bowd, Vizzeri, et al., 2009; Porciatti & Ventura, 2004; Sehi, Pin-
zon-Plazas, Feuer, & Greenﬁeld, 2009). The PERG response is a mass
potential that sums information primarily from the electrical
potentials of the inner retina and in particular the RGCs (Ben-Shlo-
mo et al., 2005; Price et al., 1988). In experimental models of glau-
coma elevated IOP has been associated with reduced PERGll rights reserved.
Eye Institute, University of
ive, Palm Beach Gardens, FLmeasurements consistent with RGC dysfunction (Johnson, Drum,
Quigley, Sanchez, & Dunkelberger, 1989; Viswanathan, Frishman,
& Robson, 2000). The glaucoma speciﬁc PERGLA algorithm has
been shown to be potentially useful as a measure of detecting early
glaucomatous damage (Bach et al., 2006; Hood et al., 2005; Parisi,
Miglior, Manni, Centofanti, & Bucci, 2006; Porciatti, Falsini, Brun-
ori, Colotto, & Moretti, 1987). It has been demonstrated that rever-
sal of RGC dysfunction can occur following pharmacologic
reduction of IOP in glaucomatous eyes with early standard auto-
mated perimetry (SAP) defects (Ventura & Porciatti, 2005). Sehi
and colleagues have recently shown that reversal of RGC dysfunc-
tion occurs following surgical reduction of IOP and may be quanti-
ﬁed using PERGLA (Sehi, Grewal, Goodkin, & Greenﬁeld, in press).
Latanoprost 0.005% (Xalatan™, Pﬁzer Inc., New York, NY) is a
synthetic, highly selective FP receptor (prostaglandin F2a receptor;
PGF2a) agonist (Resul et al., 1993) that has been demonstrated to
reduce IOP in patients with ocular hypertension (Camras, 1996; Fri-
strom & Nilsson, 1993; Hotehama, Mishima, Kitazawa, & Masuda,
1993; Nagasubramanian, Sheth, Hitchings, & Stjernschantz, 1993;
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glaucoma (Hotehama et al., 1993), normal-tension glaucoma (Rulo,
Greve, Geijssen, & Hoyng, 1996), and in normotensive subjects (Ziai,
Dolan, Kacere, & Brubaker, 1993). Prospective trials have demon-
strated a therapeutic efﬁcacy similar or superior to that of timolol
maleate 0.5% dosed twice daily (Alm et al., 1995). The ocular hypo-
tensive effect of thismedication is primarily related to an increase in
uveoscleral outﬂow, as demonstrated in primates (Bito, Stjerns-
chantz, Resul, Miranda, & Basu, 1993; Resul, Stjernschantz, Selen,
& Bito, 1997; Weinreb, 2001). Using ﬂuorophotometry, the mecha-
nism of IOP reduction in humans has been reported to involve both
increased uveoscleral and a possible mild increase in conventional
outﬂow (Dinslage, Hueber, Diestelhorst, & Krieglstein, 2004).
We hypothesized that IOP reduction, using latanoprost 0.005%
as monotherapy would improve RGC function compared to pla-
cebo. The purpose of this investigation was to evaluate the impact
of IOP reduction on RGC function measured using PERGLA in glau-
coma suspect and glaucomatous eyes receiving latanoprost 0.005%
versus placebo.2. Methods
This study was designed as a prospective, placebo-controlled,
double masked, cross-over clinical trial. Eyes categorized as peri-
metric glaucoma (PG) and glaucoma suspect (GS) meeting eligibil-
ity criteria were prospectively enrolled. Glaucomatous optic
neuropathy was deﬁned as narrowing of the neuroretinal rim,
notching, excavation, or RNFL defect. PG eyes had glaucomatous
optic nerve damage and repeatable SAP abnormality deﬁned as a
glaucoma hemiﬁeld test (GHT) ‘‘outside normal limits” or pattern
standard deviation (PSD) outside 95% normal limits. All patients
had prior SAP experience and those with SAP abnormalities had
at least one conﬁrmatory visual ﬁeld examination. Eyes with sus-
pected glaucoma consisted of eyes with ocular hypertension
(OHT) or pre-perimetric glaucoma and were categorized in a com-
bined group (GS). Patients with OHT were characterized by IOP
P24 mmHg with normal optic disks and normal SAP. Pre-perimet-
ric glaucoma patients consisted of those with glaucomatous optic
neuropathy on funduscopic examination and review of stereo-
scopic optic disk photographs but normal SAP.
All participants signed a consent form approved by the Institu-
tional Review Board for Human Research at the University of Mia-
mi that was in agreement with the provisions of the Declaration of
Helsinki. Exclusion criteria consisted of best-corrected visual acu-
ity (BCVA) less than 20/40, spherical equivalent refractive error
of >+3.00 DS or <7.00 DS, untreated IOP >32 mmHg, corneal or
retinal pathology, prior intraocular surgery except for uncompli-
cated cataract extraction, age <18 or >80 years, unreliable SAP
(>33% rate of ﬁxation losses, false positives and false negatives),Fig. 1. Flowchart illustrates the study design consisting of a screening visit and 3 diurnal
and pattern electroretinogram testing. A baseline examination was performed followin
latanoprost 0.005% or placebo for four-weeks. Subjects were then crossed over to rec
underwent repeat examination.contraindication to latanoprost 0.005%, and PERGLA signals origi-
nating from eye movement characterized by a threshold voltage
exceeding ±25 lV. All participants underwent complete ophthal-
mic examination including slit lamp biomicroscopy, dilated stereo-
scopic examination, gonioscopy, Goldmann applanation
tonometry, ultrasound pachymetry (DGH 55 Pachmate, DGH Tech-
nology Inc., Exton, PA), refraction and visual acuity measurement
and photography of the optic disk, and SAP (Carl-Zeiss Meditec,
Dublin, CA; SITA standard strategy, program 24-2) at baseline. Five
diurnal measurements consisting of PERGLA amplitude (lV) and
phase (p-radian) (PERGLA, Lace Ellectronica, Glaid Version 1.2,
Pisa, Italy), IOP and blood pressure (BP) measurements were per-
formed at the baseline session and at two sessions after randomly
receiving latanoprost 0.005% and placebo for a 4-week period. The
rationale for the 4-week duration of the treatment was based on
several studies that have demonstrated signiﬁcant IOP reduction
following a 3–4-week treatment using latanoprost (Drance, Crich-
ton, & Mills, 1998; Kiuchi, Motoyama, & Oshika, 2007; Rulo et al.,
1996). We considered two safety measures during the washout
period: (1) a safety IOP check at 2 weeks during washout (Figs. 1
and 2) a visual ﬁeld measurement at each of the four diurnal ses-
sions. The patient was excluded at the 2-week safety visit or the
ﬁrst diurnal visit if IOP rose above 32 mmHg.
Each measurement IOP, BP, and PERGLA measurement was re-
peated twice at each session and an average measurement was re-
corded. Mean ocular perfusion pressure (MOPP, in mm Hg) was
deﬁned as the difference between 2/3 of mean arterial pressure
and IOP (Gherghel, Orgul, Gugleta, Gekkieva, & Flammer, 2000).
Fig. 1 represents a ﬂowchart that illustrates the study design.
The study protocol included a screening visit and three diurnal
examinations that included ﬁve measurements between 8:00 am
and 4:00 pm consisting of IOP, BP, and PERGLA testing. One ran-
domly selected eye of each subject meeting eligibility criteria
was enrolled. A baseline examination was performed following a
4-week washout period, and repeat examination after randomly
receiving latanoprost 0.005% or placebo dosed once daily at night
for 4-weeks. A randomization list was maintained and masked
study medications were provided (Pﬁzer Inc., New York, NY) in
identical bottles labeled with the assigned randomization number
directly to the clinical center and stored under refrigeration. Sub-
jects were then crossed over to receive the alternative therapy
for 4 weeks following a second washout period, and underwent re-
peat examination.2.1. Pattern electroretinogram examination
Steady-state PERG optimized for glaucoma (PERGLA; Lace
Ellectronica, Glaid Version 1.2, Pisa, Italy) was used on both eyes
simultaneously to measure the RGC function as described by Por-examinations that included 5 measurements of intraocular pressure, blood pressure,
g a four-week washout period, and repeat examination after randomly receiving
eive the alternative therapy for 4 weeks following a second washout period, and
Fig. 2. Histogram illustrates the mean intraocular at each of ﬁve diurnal time points obtained at the baseline session compared with treatment using latanoprost 0.005% and
placebo. The IOP at the latanoprost session was signiﬁcantly (p < 0.001) lower compared with baseline and placebo at all time-points.
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rected for 30 cm. Pupils were undilated and had a diameter of
P2 mm. The skin was cleansed and prepared using electrode prep
pads. Five gold-plated electrode cups with 9 mm diameter ﬁlled
with conductive gel (Parker Laboratories, Inc.; Fairﬁeld, NJ) were
taped on the central forehead, temples and lower eyelids. A pre-
adaptation period of 3 min was allowed prior to recording PERGLA.
The PERGLA system evaluates the electrodes’ impedance automat-
ically. The impedance is considered acceptable when it is lower
than 5000 Ohm, and an LED provides feedback to the operator
regarding each electrode. There is also an oscilloscope in live mode
that provides feedback about the background noise. Black and
white horizontal bars subtending a visual angle of 25 were pre-
sented in counter-phase on a video monitor placed at 30 cm. Spa-
tial frequency was 1.64 cycle/degree and temporal frequency was
8.14 Hz (cycle/s). The target luminance was 40 cd/m2 and the back-
ground luminance was 4 cd/m2 using a 98% contrast. Each presen-
tation consisted of 300 registered sweeps after exclusion of the
ﬁrst 30 sweeps to allow a steady-state recording. There is no gaze
tracking system provided in this device. However, there is a mech-
anism incorporated that automatically rejects unacceptable signals
originating from blinking or eye movements over a threshold volt-
age of ±25 lV. The acquisition time for each sweep was 122.8 ms.
Discrete Fourier transform (DFT) was used to isolate the sinusoidal
component at the reversal frequency (16.28 Hz), and measure its
amplitude in lV (1/2 of the peak to trough amplitude) and phase
lag in p-radians compared to the stimulus frequency. A phase de-
crease of 0.1 p-radians is equivalent to 3.1 ms delay in response la-
tency (Porciatti, Sorokac, & Buchser, 2005). To help with the clinical
interpretation of results, PERGLA provides deviations of amplitude
and phase from age-predicted averages, expressed in standard
deviation (SD) units.
One experienced investigator was responsible for all aspects of
data collection for PERGLA. For each patient an average of two
measurements was used. Each measurement consisted of two sep-
arate sequential series, each of which was composed of 300 arti-
fact-free signal registrations. Outcome measures consisted of
PERGLA amplitude (lV) and phase (p-radian).2.2. Statistical analysis
Statistical analysis was performed using JMP software version
8.0 (SAS Inc., Cary, NC, USA). The sample size was calculated at
the commencement of study. The estimated sample size for an al-
pha level of 5%, and a power of 80% was 68 to detect a 0.17 lV
change in amplitude from baseline after latanoprost therapy. Stu-dent’s t-test, chi-square test, and analysis of variance (ANOVA)
with Tukey HSD were performed to compare clinical characteris-
tics between groups. Intraclass correlation coefﬁcient (ICC), coefﬁ-
cient of variability (CoV), and variance component analysis were
performed to examine the reproducibility and variability of data.
Linear mixed-effects models were constructed with both ﬁxed
and random effects included to investigate the impact of IOP,MOPP,
SAP MD, ocular diagnosis (PG, GS), treatment, time of day, IOP 
time, treatment  time, and IOP  treatment on PERGLA amplitude
and phase. Categorical and continuous variables were simulta-
neously tested for their associationwith outcomemeasures as ﬁxed
effects. Random patient effects were used to accommodate serial
dependence within patients in the responses over time. All tests
were two-sided and a p-value of <0.05 was considered signiﬁcant.3. Results
One-hundred and two patients were enrolled in this study.
Thirty-four patients were excluded for the following reasons: 23
patients withdrew prior to completion of the protocol, two patients
developed increased IOP during the washout period deemed to be
unsafe for the optic nerve, two patients developed ocular allergy,
and seven patients had poor quality PERGLA signal. Sixty-eight
eyes of 68 patients (mean age 67.4 ± 10.6 years) were included in
the analysis consisting of 35 eyes with perimetric glaucoma (PG)
and 33 glaucoma suspect (GS) eyes, comprised of nine pre-peri-
metric glaucoma (glaucomatous optic neuropathy and normal
SAP) and 24 ocular hypertensive (OHT, no optic neuropathy, nor-
mal SAP) eyes. Forty-six patients (23 glaucoma, 18 OHT, ﬁve pre-
perimetric glaucoma) were using topical anti-glaucomatous treat-
ment prior to the initiation of this study. All subjects were medi-
cally stable with controlled IOP and only non-progressing eyes
were enrolled. During the study interval, no clinically detectable
change in the optic nerve or visual ﬁeld was identiﬁed in any pa-
tient. A standard visual ﬁeld was performed at baseline and at
the conclusion of the 3-month study. Although there were insufﬁ-
cient number of visual ﬁeld examinations to statistically judge if
visual ﬁeld progression had occurred, the average SAP MD and
PSD at baseline (1.8 ± 4.3 and 2.6 ± 2.7 dB, respectively) and at
the last study visit (2.1 ± 4.9 and 2.8 ± 2.8 dB, respectively) were
similar (p = 0.36, p = 0.45).
Table 1 describes the clinical characteristics of the study popu-
lation. Baseline mean IOP, BP, MOPP, PERGLA amplitude and PER-
GLA phase were similar between the PG and GS eyes.
Mean IOP (mm Hg) after using latanoprost 0.005% for 4 weeks
(14.9 ± 3.8) was signiﬁcantly (p < 0.001) lower compared with
Table 1
Baseline clinical characteristics of the study population (n = 68).
Mean ± SD (range) PG (n = 35) GS (n = 33) p-Value
Age (yrs) 69.1 ± 8.0 65.6 ± 12.6 0.20
Gender 0.87a
Male 10 9
Female 25 24
Ethnicity 0.70a
White 27 27
African American 1 7
Other 1 5
Intraocular pressure (mm Hg) 18.8 ± 4.9 (10–36) 18.9 ± 4.0 (12.2–32.4) 0.80
PERGLA amplitude (lV) 0.48 ± 0.20 0.17–1.49) 0.50 ± 0.27 (0.08–1.65) 0.39
PERGLA phase (p-radian) 1.69 ± 0.20 (1.28–2.37) 1.69 ± 0.17 (1.14–2.20) 0.92
Systolic blood pressure (mm Hg) 128.3 ± 12.9 (100–164) 129.1 ± 13.1 (108–172) 0.57
Diastolic blood pressure (mm Hg) 78.6 ± 8.7 (60–107) 80.2 ± 6.9 (49.5–98) 0.06
Ocular perfusion pressure (mm Hg) 44.7 ± 7.9 (22.5–65.3) 45.5 ± 6.8 (28.8–64.2) 0.34
SAP mean deviation (dB) 2.4 ± 3.6 (17.24 to 1.98) 0.16 ± 1.7 (2.66 to 2.23) <0.001
SAP pattern standard deviation (dB) 3.3 ± 2.7 (1.03–13.4) 1.8 ± 0.7 (1–2.2) <0.001
Student’s t-test; SD = standard deviation; PG = perimetric glaucoma; GS = glaucoma suspect; PERGLA = pattern electroretinogram optimized for glaucoma;
SAP = standard automated perimetry.
* Chi-square.
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tion of 20 ± 13%. As illustrated in Fig. 2, the IOP using latanoprost
was signiﬁcantly (p < 0.001) less than baseline and placebo at all
time-points measured during the diurnal period. Peak IOP (using
latanoprost or placebo) was at 8:00–10:00 am; and trough IOP
was at 2:00 pm. MOPP (mm Hg) using latanoprost (48.1 ± 6.0)
was signiﬁcantly (p < 0.001) greater compared to baseline
(45.1 ± 7.4) or placebo (44.6 ± 6.2).
Mean PERGLA amplitude (lV) and phase (p-radian) using
latanoprost 0.005% (0.49 ± 0.22 and 1.71 ± 0.22, respectively) were
similar (p > 0.05) to baseline (0.49 ± 0.24 and 1.69 ± 0.19) and pla-
cebo (0.50 ± 0.24 and 1.72 ± 0.23). The amounts of amplitude devi-
ation from normal (in SD unit) at the baseline (2.28 ± 1.97),
placebo (2.34 ± 1.84) and latanoprost sessions (2.37 ± 1.85)
were similar (p > 0.05). The amplitude deviation was outside 2 SD
from age-predicted normals in 19 glaucoma suspect and 17 glauco-
matous eyes. Fig. 3 represents a box-and-whisker plot illustrating
the distribution of PERGLA amplitude (A) and phase (B) values at
baseline, latanoprost and placebo sessions. The whiskers represent
the minimum and maximum values; the ends of the box represent
the 25th and 75th percentiles and the horizontal line inside the
box represents the median at the 50th percentile value.Fig. 3. Distribution of pattern electroretinogram amplitude (A) and phase (B) values at th
and maximum values; the ends of the box represent the 25th and 75th percentiles and thFig. 4 represents a scatter plot of PERGLA amplitude (A) and
phase (B) stratiﬁed by ocular diagnosis (GS and PG) and demon-
strates similar (p > 0.05) values at baseline compared with latano-
prost treatment. A more than 84% increase in PERGLA amplitude
due to latanoprost therapy was observed in four OHT females
who were between 62 and 76 years of age, had no optic neuropa-
thy and were all under topical anti-glaucomatous treatment prior
to washout and participation in the study. The amount of IOP de-
cline was between 3 and 8.4 mm Hg at the latanoprost session
compared to baseline in these four patients. We examined the rela-
tionship between change in IOP and change in PERGLA amplitude
(Fig. 5) and PERGLA phase and found no signiﬁcant association
(p > 0.05).
Table 2 demonstrates the PERGLA amplitude (A) and phase (B)
using latanoprost 0.005% compared with placebo at each diurnal
time point. Neither PERGLA amplitude nor PERGLA phase showed
any signiﬁcant change at any timepoint using latanoprost compared
to placebo (p > 0.05). There was no signiﬁcant interaction between
treatment and time of day for either PERGLA amplitude (p = 0.14)
orphase (p = 0.42)and its inclusiondidnot alter the statistical signif-
icance of the other variables in the model. Table 3 summarizes the
results of linear mixed-effects models and demonstrates that thee baseline, latanoprost and placebo sessions. The whiskers represent the minimum
e horizontal line inside the box represents the median at the 50th percentile value.
Fig. 4. Scatter plot of pattern electroretinogram amplitude (A, left) and phase (B, right) values demonstrates similar values at baseline compared with latanoprost 0.005%
treatment among the study population of glaucoma suspects (GS) and eyes with perimetric glaucoma (PG).
Fig. 5. Scatter plot of pattern electroretinogram (PERGLA) amplitude values
illustrates the relationship between change in PERGLA response and change in
intraocular pressure after latanoprost 0.005% treatment among the study popula-
tion of glaucoma suspects (GS) and eyes with perimetric glaucoma (PG).
Table 2
PERGLA amplitude (A) and phase (B) using latanoprost 0.005% compared with placebo
at each diurnal time point.
Time Placebo Latanoprost Difference
Mean SE Mean SE Mean SE p-Value
A. PERGLA amplitude (lV)
8:00 0.50 0.03 0.47 0.03 0.03 0.04 0.40
10:00 0.51 0.03 0.50 0.02 0.02 0.04 0.68
12:00 0.49 0.03 0.54 0.03 0.05 0.04 0.21
14:00 0.498 0.03 0.486 0.03 0.01 0.04 0.76
16:00 0.49 0.03 0.47 0.03 0.02 0.04 0.63
B. PERGLA phase (p-radian)
8:00 1.68 0.02 1.71 0.03 0.03 0.03 0.30
10:00 1.68 0.02 1.71 0.02 0.03 0.03 0.33
12:00 1.74 0.03 1.69 0.02 0.05 0.04 0.23
14:00 1.73 0.03 1.70 0.03 0.03 0.04 0.39
16:00 1.76 0.03 1.73 0.03 0.04 0.03 0.27
SE = standard error.
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time of day, treatment with latanoprost or placebo, IOP, severity of
visual ﬁeld loss, MOPP or any other clinical parameter.
We examined the reproducibility and variability of PERGLA
measurements using the intraclass correlation coefﬁcient (ICC)
and coefﬁcient of variation (CoV), assuming that the change in var-
iability between sessions was not due to the effect of differing
treatments during the periods of the crossover. It is likely that this
analysis underestimates the actual reproducibility of our measure-
ments, since it does not include true within or between trial repli-
cates. The ICC (PERGLA amplitude and phase) was 0.73 and 0.40 at
baseline, and 0.72 and 0.43 using latanoprost. The CoV (PERGLA
amplitude and phase) was 24.2% and 9% at baseline, and 22.8%
and 10.1% using latanoprost. Table 4 demonstrates variance com-
ponent estimates for pattern electroretinogram optimized for glau-
coma (PERGLA) amplitude and phase at the baseline and
latanoprost sessions. For PERGLA amplitude the highest variance
component was due to patient variance but not for PERGLA phase.
In this analysis measurements made at different times were con-sidered as ﬁve replicate measures. At the latanoprost session the
variability caused by differences between patients, was reduced
compared with baseline.
The PERGLA provides measures of variability, and noise for
amplitude and phase. The amplitude variability (0.32 ± 0.24;
0.34 ± 0.23; 0.32 ± 0.31 respectively) and noise (0.18 ± 0.12;
0.17 ± 0.15; 0.16 ± 0.15 respectively) were similar (p > 0.05) at
the baseline, placebo and latanoprost sessions. We calculated the
signal-to-noise ratio (SNR) at each diurnal session (signal ampli-
tude divided by noise level). The SNRs at the baseline, placebo,
and latanoprost diurnal sessions (2.95 ± 2.21; 3.08 ± 2.17;
3.23 ± 2.15) were similar (p > 0.05, one way ANOVA).
4. Discussion
The total RGC population in a glaucomatous eye consists of
RGCs that are physiologically normal, dysfunctional, nonviable,
and atrophic undergoing variable stages of degeneration. Quantiﬁ-
cation of RGC function is of considerable interest to clinicians and
scientists who seek biomarkers for early diagnosis, prediction and
identiﬁcation of progression, and response to therapeutic interven-
tions. Measurement of RGC dysfunction would also serve as a use-
ful endpoint for glaucoma clinical trials involving IOP lowering and
potentially non-IOP lowering therapy.
Table 3
The relationship between diurnal PERGLA amplitude and phase with various clinical parameters at different sessions, using linear mixed-effects models.
PERGLA amplitude (lV) PERGLA phase (p-radian)
Estimate SE p-Value Estimate SE p-Value
IOP (mm Hg) 0.003 0.002 0.14 0.0009 0.002 0.68
Time 0.54 0.063
8:00 0.009 0.010 0.016 0.013
10:00 0.003 0.010 0.025 0.013
12:00 0.016 0.010 0.007 0.013
14:00 0.004 0.010 0.004 0.013
16:00 Reference Reference
Treatment session 0.17 0.26
Baseline 0.015 0.008 0.015 0.010
Latanoprost 0.012 0.009 0.004 0.011
Placebo Reference Reference
IOP  timea 0.094 0.36
Treatment  time a 0.058 0.38
Treatment  IOPa 0.26 0.42
Ocular diagnosis 0.54 0.38
GS 0.014 0.02 0.011 0.012
PG Reference Reference
Mean deviation (dB) 0.006 0.004 0.15 0.002 0.004 0.44
Mean ocular perfusion pressure (mm Hg) 0.001 0.001 0.40 0.001 0.001 0.40
IOP = intraocular pressure; BL = baseline; PG = perimetric glaucoma; GS = glaucoma suspect.
Reference = in a linear model, one of the outcome categories for each ﬁxed effect serves as the reference category and the response of other categories is examined relative to
it.
a Coefﬁcients and standard errors of non-signiﬁcant interactions omitted.
Table 4
Variance component estimates for pattern electroretinogram optimized for glaucoma (PERGLA) amplitude and phase at the baseline and latanoprost
sessions. For PERGLA amplitude the highest variance component was due to patient variance but not for PERGLA phase. In this analysis
measurements made at different times were considered as ﬁve replicate measures.
Parameter Variance component Parameter estimate Percentage of total variance (%)
PERGLA amplitude at baseline Patients 0.04 73.1
Time 0.0002 0.4
Unexplained variability 0.01 26.5
PERGLA amplitude at latanoprost session Patients 0.03 67.8
Time 0.0005 1.0
Unexplained variability 0.02 31.2
PERGLA phase at baseline Patients 0.01 36
Time 0.0002 0.6
Unexplained variability 0.02 63.4
PERGLA phase at latanoprost session Patients 0.009 17.6
Time 0.00 0
Unexplained variability 0.04 82.4
PERGLA = pattern electroretinogram optimized for glaucoma.
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marker for RGC dysfunction. Ventura and Porciatti (2005) retro-
spectively reported that the recovery of PERGLA amplitude might
indicate the reversal of RGC dysfunction as observed in 12 of 25
glaucomatous eyes that underwent various methods of pharmaco-
logic reduction in IOP during a 1–3 month period of time. Porciatti
and Nagaraju (2010) showed that in a mouse model of glaucoma
head-up body posture causes IOP reduction (5–6 mm Hg) and
improvement of PERGLA amplitude within a 20-min time frame.
They suggest that the observed improvement of PERGLA amplitude
is consistent with IOP-dependent reversible RGC dysfunction.
Wittstrom et al. (2010) showed improvement in multifocal ERG
among 11 glaucomatous eyes after trabeculectomy. In a prospec-
tive study of 47 eyes that underwent surgical IOP reduction for
uncontrolled IOP, Sehi et al. (in press) recently reported that the
mean postoperative PERGLA amplitude (0.46 ± 0.22 lV) signiﬁ-
cantly increased compared to preoperative PERGLA amplitude
(0.37 ± 0.18 lV). A 50% postoperative reduction in IOP was
achieved compared to baseline (20 mm Hg). No change in PERGLA
response was observed among un-operated fellow eyes.In the present study, we designed and executed a prospective
randomized placebo-controlled cross-over clinical trial designed
to examine the relationship between IOP reduction and RGC func-
tion measured using PERGLA. Latanoprost and placebo were
administered and both investigator and patient were masked to
identity of the treatment. Using latanoprost, a mean 20% reduction
in IOP from baseline (approximately 19 mm Hg) was observed at
all diurnal time-points, which is consistent with prior reports in
normotensive eyes (Cheng, Cai, & Wei, 2009). Latanoprost has been
reported to reduce IOP approximately 20% in normal eyes (Mishi-
ma, Kiuchi, Takamatsu, Racz, & Bito, 1997), and 21% in eyes with
normal-tension glaucoma (Cheng et al., 2009; Rulo et al., 1996).
Eyes treated with latanoprost had similar PERGLA responses com-
pared to eyes receiving placebo. No association was identiﬁed be-
tween IOP reduction and PERGLA amplitude after accounting for
age and severity of disease.
Other studies have failed to show a reversal of RGC dysfunction
as a result of moderate IOP reduction. Tytla, Trope, and Buncic
(1990) measured ﬂicker sensitivity among a group of OHT and
POAG patients before, during and after IOP lowering treatment
M. Sehi et al. / Vision Research 51 (2011) 235–242 241with timolol 0.5% and examined temporal contrast sensitivity in
treated eyes compared to untreated normal controls. They found
that 100% of eyes with POAG and 65% of eyes with ocular hyperten-
sion had no improvement in ﬂicker sensitivity. Nesher, Trick, Kass,
and Gordon (1990) examined the PERG in 21 patients with ocular
hypertension who had received unilateral timolol 0.5% therapy for
a minimum of 6 years and found that mean PERG amplitude was
similar between placebo-treated and timolol-treated eyes.
When studies arrive at different conclusions, one must critically
compare the methodology, study population, and analysis methods
used in each study to help explain the apparent differences in out-
comes. The magnitude of IOP reduction in the present study (20%)
and in other studies using timolol 0.5%, (Nesher et al., 1990; Tytla
et al., 1990) was less than the amount of IOP reduction observed
after incisional glaucoma surgery (50%) (Sehi et al., in press) which
may have contributed to our inability to identify an improvement
in PERGLA response. The baseline IOP in our study (19 mm Hg) was
related to enrollment of eyes with normal-tension glaucoma and
glaucoma suspects, and may have contributed the results we ob-
served. Many studies have demonstrated that PERG amplitude is
diminished in early glaucoma (Ringens, Vijfvinkel-Bruinenga, &
van Lith, 1986) (Bach & Hoffmann, 2008; Bach & Speidel-Fiaux,
1989; Bach et al., 2006; Falsini et al., 2008; Hood et al., 2005; Marx
et al., 1988; Porciatti et al., 1987; Riva et al., 2004; Ventura, Porci-
atti, Ishida, Feuer, & Parrish, 2005; Ventura, Sorokac, De Los Santos,
Feuer, & Porciatti, 2006) and may be unable to detect further
change in eyes with moderate or advanced glaucoma due to the
narrow dynamic range of amplitude measurements and overlap
between normal and glaucomatous eyes (Sehi et al., 2009; Yang
& Swanson, 2007). PERGLA responses may be associated with
non-RGC cell populations and may not reﬂect isolated RGC func-
tion (Demb, 2008; Viswanathan, Frishman, Robson, Harwerth, &
Smith, 1999) Although a large part of the PERGLA biopotential is
generated by RGCs, but it still depends on the responses from the
entire circuitry and might still be affected to a lesser degree by
non-RGC populations.(Demb, 2008; Viswanathan, Frishman, Rob-
son, & Walters, 2001). PERGLA amplitude is strongly correlated
with visual acuity and media opacity (Porciatti & Ventura, 2004)
therefore care must be taken to exclude eyes with moderate cata-
ract or poor vision. Finally, We observed moderate variability of
PERGLA measurements in our study consistent with previous re-
ports (Bowd, Tafreshi, et al., 2009; Bowd, Vizzeri, et al., 2009; Fre-
dette, Anderson, Porciatti, & Feuer, 2008; Porciatti and Ventura,
2004; Sehi et al., 2009; Yang and Swanson, 2007). Using a variance
component analysis we found that the largest component of total
variability was due to overall differences between patients, and
was not due to repeated measures at different time-points. It is
possible that PERGLA variability may limit its ability to detect
reversal of RGC dysfunction. It is also possible that a modest de-
crease in IOP (20%) may be insufﬁcient to improve the signal gen-
erated by the RGC population.
To our knowledge, this report describes the ﬁrst prospective
randomized placebo-controlled cross-over clinical trial designed
to examine the relationship between IOP reduction and RGC func-
tion measured using PERGLA. In this study with an average IOP
reduction of 20% from baseline, latanoprost 0.005% monotherapy
was not associated with improvement in PERGLA response. Further
prospective studies with more robust IOP lowering are warranted
in order to better understand the relationship between IOP and
PERGLA response, and the potential role of PERGLA as a biomarker
for RGC dysfunction in glaucoma clinical trials.
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